EGFR and non-small cell lung carcinoma: In recent decades, the development of immune checkpoint inhibitors (ICI) and agents targeting specific oncogenic driver mutations (EGFR, ALK, ROS, BRAF, MET, RET, ERBB2 and NTRK) has fundamentally changed the therapeutic landscape of NSCLC by prolonging survival rates and reducing toxicities associated with conventional chemotherapy (3).